1/2 Area ViewPlate-96 well Microplates, PS, TC, White, Sterile, Case of 40 | PerkinElmer

幸运8平台彩票

PerkinElmer
check quantity

1/2 Area ViewPlate-96 well Microplates, PS, TC, White, Sterile, Case of 40

幸运8平台彩票 96-well white with clear bottom 1/2 area microplate with tissue culture treatment (TC-treated) for cell-based assays. Half-area plates utilize the same well spacing as a regular 96-well plate, but contain wells with half the diameter of a typical 96-well plate. This enables miniaturization to lower assay volumes while retaining ease-of-pipetting.

项目已成功添加到购物车

部件号
产品尺寸
6005760
Case of 40
更多
6005768
Case of 160
更多
立即购买

请输入有效的数量

请登录后再添加至收藏夹

幸运8平台彩票 购物车为空

详情 信息

幸运8平台彩票PerkinElmer's ½ AreaPlate offers same well depth at half the size to help you miniaturize your assay, designed to utilize cost reduction advantages without going to a 384-well format.

Leveraging years of assay and instrument experience in plate detection, PerkinElmer designs better microplates for better performance that guarantees better results for all PerkinElmer applications.

规格

自动化兼容 Yes
涂层处理 TC-treated, Sterile
颜色 White/Clear Bottom
检测方法 Time-Resolved Fluorescence (TRF), Luminescence, Radiometric
产品品牌名称 1/2 AreaPlate, ViewPlate
包装量 40.0 Units
运输条件 环境
Sterile Yes
产品尺寸 Case of 40
阱数量 96 well plate
阱形状 1/2 Area
资源,活动及更多信息
  • 所有

应用文献

Measuring PD-L1 Expression in Breast Cancer Cell Lines with AlphaLISA

Too many candidates, too little time. The lack of robust, rapid, high-throughput assays to identify and qualify potential therapeutic targets in areas such as cancer research continues to cost valuable time. What if you could increase assay throughput without compromising sensitivity, obtain more data points from each sample and eliminate tedious wash steps? Find out how AlphaLISA® assay technology, combined with the EnVision® multimode plate reader, provides a fast, powerful, homogeneous platform for screening potential inhibitors of PD-L1 (a protein associated with breast cancer tumor cells) expression in human cells.

PDF 4 MB
Measuring PD-L1 and PD-1 Expression in Human Cells with LANCE Ultra TR-FRET

幸运8平台彩票Immuno-oncology is an exciting area within cancer research and among the most promising approaches to activating therapeutic antitumor immunity is through the blockade of immune checkpoints. The programmed cell death-1 (PD-1) immune checkpoint pathway is a negative regulator of T cell immune function. When PD-1 is bound to programmed cell death-ligand 1 (PD-L1), T cell response is suppressed. Many tumor cells escape anti-tumor immunity through their expression of Programmed Death Ligand 1 (PD-L1 or B7-H1), which interacts with T cell-expressed PD-1 and results in T cell apoptosis. PD-L1 expression has been studied in multiple different cancers. While several anti-PD-1 or PD-L1 monoclonal antibodies that block the PD-1/ PD-L1 complex formation have been developed to date, there remains a need for more robust, rapid, high-throughput assays to identify and qualify novel inhibitors of PD-1/PD-L1 binding and assays to detect expression levels of both binding partners. Find out how LANCE® Ultra Technology provides a fast, powerful, homogeneous platform for identifying and characterizing endogenous PD-L1 and PD-1 expression in human cells.

PDF 4 MB

数据单表